Leading Micros (衔微医疗), a Beijing-based surgical robot startup specializing in ophthalmic solutions, has announced an angel+ round of funding worth tens of millions of yuan, backed by Redhill Capital and Beijing Medical Robots Industry Innovation Center.
Founded in June 2022, Leading Micros has derived its core technologies from the R&D efforts of Beihang University. The founding team has more than 10 years of experience in developing ophthalmic robotic systems.
Their research was published in Handbook of Robotic and Image-Guided Surgery, a collection of research papers written by leading experts on surgical robotics.
Currently, Leading Micros looks to facilitate the type approval and certification of its third-generation ophthalmic surgical robots.
In the meantime, it is working to land a license from the National Medical Product Administration (NMPA) for its other products in the pipelines, including one for the treatment of dry eye syndrome.
The startup claims to be on par technologically with world industry leaders, and boast advantages in smart sensing and control of robotic end actuators.
China’s ophthalmic surgical equipment market has ridden on the waves of huge patient demand in recent years.
Ophthalmic robots will help more doctors perform subretinal injection surgeries that only a few topnotch institutions in first-tier cities were capable of.
Besides, they can also help complete subretinal blood vessel thrombolytic injection, a highly intractable procedure that was almost unheard of previously at domestic hospitals.
All these potential applications will increase the number of cures for subretinal diseases and benefit a wider population of patients.
